Accelera (Nerviano Medical Sciences Group) selected by Karolinska Development as preferred provider for pre-clinical research and signs a framework agreement for the supply of services

Milan, 7 November 2013 – A prestigious new international agreement characterizes the new course of the Nerviano Medical Sciences Group, reinforcing its important role in the international biomedical research scene. Accelera, the company acting as preclinical CRO (Contract Research Organisation) within the NMS Group organization, supporting leading pharmaceutical and biotech companies at national and international levels, recently signed an important framework agreement for the supply of services with the Karolinska Development, a life science investment company listed on the NASDAQ OMX Stockholm Stock Exchange (ticker: KDEV).
This agreement recognizes Accelera as preferred partner of Karolinska Development portfolio companies for pre-clinical research activities. From now on, business projects and start-ups supported by the Swedish investment company – currently 25, with 35 projects under way in a wide range of fields of medical and pharmacological research – will have easier access to Accelera’s services for pre-clinical development activities.
The agreement both confirms and consolidates the outstanding research and development activities conducted at all levels by NMS, a centre already recognised worldwide and by the leading players on the international pharmaceutical and biotech markets. Accelera, which is operating since some years on the Swedish market and has developed positive business relations, now aims to increase its share of revenue from Scandinavia by over 30%.

Accelera – NMS Group
Accelera is the pre-clinical CRO (Contract Research Organisation) within the NMS Group, offering to pharmaceutical and biotech companies at national and international. high-quality and integrated pre-clinical services to support all phases of their research and development programs, from the selection of the most promising molecules to the preparation of the documentation required for approval from the regulatory authorities. Cutting-edge systems, advanced technologies, qualified scientific staff and acknowledgments from the Regulatory Agencies (GLP Compliance) guarantee the reliability of the results obtained in Accelera facilities, as well as ensuring they are fully accessible at international level. For further information: http://www.accelera.info/

Karolinska Development
Karolinska Development aims to create value for patients, researchers, and investors by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 35 projects, of which 16 are in clinical development. For more information, please visit www.karolinskadevelopment.com.
Nerviano Medical Sciences is the largest company in Italy, and among the most important in Europe, in the field of pharmaceutical research and development in oncology. NMS is already able to boast important cooperation or licensing agreements with pharmaceutical and biotech companies such as Genentech (Roche), Pfizer, Novartis and Servier, as well as with the world of academia. On 31 December 2011 the Lombardy Region became the major shareholder of NMS, through the FRRB (Regional Foundation for Biomedical Research).

For further information on Nerviano Medical Sciences: http://www.nervianoms.com
Barabino & Partners Tel. 02
Stefania Bassi Mob. 335 62.82.667 s.bassi@barabino.it
Marco Catalani Mob. 340 64.62.551 m.catalani@barabino.it



To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.